Anti-oxidant capacity. The oxygen radical absorbance capacity (ORAC), ferric reducing ability of plasma (FRAP) and 2,2′-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid) (ABTS) antioxidant assays were determined as previously described by Ou et al. [41 (link)], Benzie and Strain [42 (link)], and Re et al. [43 (link)], respectively. The results were expressed as mM Trolox per 100 g of dm.
Anti-diabetic and anti-obesity activity. The α-amylase, α-glucosidase and pancreatic lipase were determined as previously described by Nowicka and Wojdyło [34 (link)] and Tkacz et al. [15 (link)]. The acarbose and orlistat was included as a positive control for α-amylase, α-glucosidase and pancreatic lipase, respectively, and the obtained results are presented as IC50 in mg/mL, i.e., the amount of the sample that is able to reduce enzyme activity by 50%.
Anti-cholinergic activity. The acetylcholinesterase (AChE) and butylcholinesterase (BuChE) inhibitions were determined as previously described by Wojdyło et al. [37 (link)]. The results are expressed as % of inhibition.
All tests: anti-oxidant (ABTS, ORAC, FRAP), α-amylase, α-glucosidase, anti-lipase, and anti-cholinergic activity were performed in triplicate using a microplate reader SynergyTM H1 (BioTek, Winooski, VT, USA).
Anti-diabetic and anti-obesity activity. The α-amylase, α-glucosidase and pancreatic lipase were determined as previously described by Nowicka and Wojdyło [34 (link)] and Tkacz et al. [15 (link)]. The acarbose and orlistat was included as a positive control for α-amylase, α-glucosidase and pancreatic lipase, respectively, and the obtained results are presented as IC50 in mg/mL, i.e., the amount of the sample that is able to reduce enzyme activity by 50%.
Anti-cholinergic activity. The acetylcholinesterase (AChE) and butylcholinesterase (BuChE) inhibitions were determined as previously described by Wojdyło et al. [37 (link)]. The results are expressed as % of inhibition.
All tests: anti-oxidant (ABTS, ORAC, FRAP), α-amylase, α-glucosidase, anti-lipase, and anti-cholinergic activity were performed in triplicate using a microplate reader SynergyTM H1 (BioTek, Winooski, VT, USA).
Free full text: Click here
